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Abstract
Background: Natural killer (NK) cells have both cytolytic and immunoregulatory functions. We recently described that these
cells release the inflammatory cytokines IL-17 and IFN-c. However, the precise identity of the NK cell subset(s) that secrete
these cytokines is not known.
Methodology/Principal Findings: To isolate the cells secreting IL-17 and IFN-c, we took advantage of the findings that
Th17/Th1 cells express chemokine receptors. Therefore, CD56
+NK cells were stained with antibodies against various
chemokine receptors and intracellularly with antibodies toward IL-17 and IFN-c. Consequently, we identified previously
unrecognized subset of NK cells generated from normal human peripheral blood after activation with IL-2 but not PMA plus
ionomycin. The cells are characterized by the expression of CD56
+ and CCR4
+, produce IL-17 and IFN-c and are consequently
named NK17/NK1 cells. They also express CD161, NKp30, NKp44, NKp46, NKG2D, CD158, CCL22, IL-2Rb and the common c
chain but not CD127 or IL-23R. Further, they possess T-bet and RORct transcription factors. Antibodies to IL-1b, IL-6, IL-21, or
TGF-b1 do not inhibit IL-2-induced generation of NK17/NK1 cells, suggesting that IL-2 has the capacity to polarize these
cells. Notably, NK17/NK1 cells are abundant in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS) without
activation, and are generated from the peripheral blood of these patients after activation with IL-2.
Conclusions/Significance: NK17/NK1 cells identified here have not been previously described in healthy or MS patients.
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Introduction
Natural killer (NK) cells represent the first line of defence against
infections and tumor metastases [1]. These cells possess immuno-
regulatoryactivitiesbysecretingmultiplecytokinesand chemokines,
and interact with dendritic cells to shape the innate and adaptive
immuneresponses.Traditionally,humanNKcellsareclassifiedinto
two major subsets; regulatory cells expressing CD56 but not CD16
known as CD56
+/highCD16
2, and cytolytic cells expressing CD16
and low or no CD56 known as CD56
2/lowCD16
+[reviewed in 2].
In addition, NK cells have been classified into NK1 and NK2
subsets based on cytokine release [3], and divided into different
subsets based on their expression of chemokine receptors [4].
A unique subset of NK cells lining human peyers patches or
tonsils that express NKp44 and CCR6 has been also described. The
cells have no cytotoxic granules, do not secrete IFN-c and IL-17,
but secrete IL-22, and were consequently designated as ‘‘NK22’’
cells [5]. Similar cells were reported by Cupedo et al. who
demonstrated that cells with lymphoid tissue inducers (LTi)
phenotype, i.e. CD127
+, lymphotoxin
+ and the nuclear factor
retinoic acid-related orphan receptor (RORC
+), can differentiate









high NK cells in intestinal lamina propria were found to
secrete the Th17 cytokine IL-22 [7]. In tonsil tissues, NK cells in




as well as secreting IL-22 and IL-26 but not IL-17, have also been
described [8]. Collectively, these observations identified NK cells
foundatmucosaltissuesthatsecreteIL-22andexpressamongmany
markers RORct and CCR6. These findings also suggest that NK
cells may be involved in autoimmune diseases by releasing
inflammatory cytokines such as IL-17 and IL-22.
The role of NK cells in autoimmune diseases has not been
delineated with precision. It was suggested that these cells play
important roles in these diseases and they could be targets for
therapy [9]. However, the role of NK cells in multiple sclerosis
(MS) is controversial as there are two schools, one indicates that
NK cells ameliorate the disease, whereas the other suggests that
they exacerbate it [reviewed in 10]. It was reported that IL-2-
activated NK cells release IL-17 and IFN-c [11,12], but the
identity of the cells that secrete these cytokines and their relation to
the recently described NK cells in the gut mucosa or tonsils are not
known. In fact, very little is known about the different subsets of
NK cells and the function of these subsets. The purpose of this
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26780report is to isolate and characterize NK cells that secrete IL-17 and
IFN-c from normal individuals and from patients with MS.
Materials and Methods
Antibodies
PE-conjugated mouse anti-NKp30 (CD337), PE-conjugated
mouse anti-NKp44 (CD336), PE-conjugated mouse anti-NKp46
(CD335), PE-conjugated mouse anti-NKG2D (CD314), PE-
conjugated mouse anti-CD161, FITC-conjugated anti-CD3,
and FITC-conjugated anti-CD19 and PE-conjugated IgG1
isotype control were purchased from Becton-Dickinson (San
Diego, CA). FITC-conjugated mouse anti-IL-17A, APC-conju-
gated anti-IL17, PE-conjugated rat anti-RORct, PE-conjugated
rat anti-T-bet, mouse and rat IgG isotype controls were
purchased from eBioscience (San Diego, CA, USA). Mouse
anti-CCR4, mouse anti-CCR6, mouse anti-CCR7, mouse anti-
CXCR3, FITC-conjugated mouse anti-CCR4, FITC-conjugated
mouse anti-CCR6, FITC-conjugated mouse anti-CCR7, FITC-
conjugated mouse anti-CCR9, FITC-conjugated mouse anti-
CXCR1, FITC-conjugated mouse anti-CXCR3, FITC-conjugat-
ed anti-mouse CXCR4, PE-conjugated mouse anti-CD158, PE-
conjugated mouse anti-CD127 (IL-7Ra), PE-conjugated mouse
anti-CD132 (common c chain), PE-conjugated mouse anti-IL-
2Rb, PE-conjugated mouse anti-IL-17, PE-conjugated mouse
anti-IFN-c, PE-conjugated mouse anti-IL-23R, PE-conjugated
mouse anti-CCL22 (MDC), mouse anti-human mouse IL-1b,
mouse anti-human IL-6, goat anti-human anti-TGF-b1, mouse
IgG1, mouse IgG2B, mouse IgG2A, rat and goat IgG were all
purchased from R&D Systems (R&D Systems Europe Ltd.,
Abingdon, UK). FITC-conjugated anti-CD14 and FITC-conju-
gated anti-CD56 were obtained from Immunotools (Friesoythe,
Germany).
NK cell isolation
Buffy coats from healthy volunteers were obtained from the
blood bank (Ulleva ˚l Hospital, Oslo, Norway). NK cell isolation
was performed using RosetteSep human NK cell enrichment
cocktail (Stem cell technologies SARL, Grenoble, France).
Approximately 50 mL buffy coat was diluted 1:1 with RPMI
medium and incubated with 25 mL of the cocktail provided with
the kit for 20 min at room temperature. Afterwards, the mixture
was centrifuged at 1800 rpm for 25 min, using Histopaque
(Sigma-Aldrich, Oslo, Norway), and NK cell layer collected. The
cells were further sorted into CD56
+ and CD56
2 cells by magnetic
separation, using EasySep human CD56 positive selection kit
(Stem cell technologies SARL). After separation both CD56
+ and
CD56
2 cells were collected. To activate the cells, NK cells isolated
by RosetteSep human NK cell enrichment cocktail (not yet
separated with CD56 cocktail), were incubated at 1610
6/mL with
200 U/mL IL-2. IL-2 (200 U/mL) was added to the cultures after
2, 4 and 6 days. The cells were collected after 7 days and then
separated into CD56
+ and CD56
2. Activation with Phorbol 12-
myristate 13-acetate (PMA) and ionomycin (both from Sigma-
Aldrich, Oslo, Norway) was done by incubating isolated
CD56
+cells with 100 ng/mL of PMA and Ionomycin each for
24 h. Cells were washed and stained with surface anti-CCR4, and
intracellularly with anti-IL-17 and anti-IFN-c. CCR4 gated cells




+ NK cells (1610
6/
mL) were mixed with 1 mg/ mL of anti-CCR4 in 12 mL tubes,
and the mixtures were incubated for 45 min at 4uC. The cells were
washed twice with PBS plus 1% BSA, and incubated with goat
anti-mouse DYNALH magnetic beads (Invitrogene, Oslo, Norway)
for 60 min at 4uC. Cells that attached to the beads and those that
did not attach were isolated and tested for purity by flow
cytometry.
Flow cytometric analysis
For single color surface analysis, 3610
5 cells/well were labeled
in the dark at 4uC for 45 min with 0.1 mg/well FITC-conjugated
anti-CD3, 0.15 mg/well FITC-conjugated anti-CD14 and 0.1 mg/
well FITC-conjugated anti-CD19, 0.06 mg/well PE-conjugated
anti-CD127, 0.06 mg/well PE-conjugated anti-CD158, 2.5 mL PE-
conjugated anti-CD161, 0.12 mg/well PE-conjugated anti-IL-23R,
0.5 mg/well anti-NKp30, 0.5 mg/well PE-conjugated anti-NKp44,
0.5 mg/well PE-conjugated anti-NKp46, 0.5 mg/well PE-conju-
gated anti-NKG2D, 0.06 mg/well PE-conjugated anti-IL-2Rb or
isotype control antibodies. To stain intracellular molecules, cells
were fixed with 4% paraformaldehyde for 15 min at 4uC, washed
twice with SAP buffer and then labeled with 0.5 mg/well PE-
conjugated anti-RORct, 0.5 mg/well PE-conjugated anti-T-bet,
0.12 mg/well PE-conjugated anti-CCL22, 0.06 mg/well PE-con-
jugated anti-IL-2Rc or isotype control antibodies. Gating was
done according to the isotype controls. The cells were washed and
then examined in the flow cytometry ((FACSCalibur, Becton
Dickinson Biosciences, San Jose, CA).
To satin with the chemokine receptor and one intracellular
cytokine, cells were incubated with 10 mg/mL Brefeldin A for
4 hours. They were labeled at 3610
5 cells/200 mL/well with
0.06 mg/well FITC labeled anti-CCR4, 0.06 mg/well FITC-
conjugated anti-CCR6, 0.06 mg/well FITC-conjugated anti-
CCR7, 0.25 mg/well FITC-conjugated anti-CCR9, 0.12 mg/
well FITC-conjugated anti-CXCR1, 0.12 mg/well FITC-conju-
gated anti-CXCR3, 0.12 mg/well FITC-conjugated anti-
CXCR4, or isotype control antibodies for 45 min at 4uCi n
the dark. After incubation, the cells were fixed with 4%
paraformaldehyde for 15 min at 4uC and then washed twice
with SAP buffer before staining with intracellular markers as
follows: 3610
5 cells/well were incubated with 0.06 mg/well PE-
conjugated anti-IL-17, 0.06 mg/well anti-PE-conjugated IFN-c,
0.06 mg/well PE-conjugated anti-CCL3, 0.06 mg/well PE-con-
jugated anti-CCL4 or isotype controls antibodies, in the dark at
4uC for 45 min. Cells were washed with flow cytometric
medium, resuspended with the same medium and transferred
from plates into 5 ml tubes to perform flow cytometric analysis.
Compensation was done according to the isotype controls.
Analysis was done by FlowJo (Flow cytometry analysis software,
Ashland, OR, USA).
For three color analysis, 1610
6 cells/well were labeled with
0.125 mg/well FITC-conjugated anti-CCR4, 0.125 mg/well
FITC-conjugated anti-CCR6, 0.125 mg/well FITC-conjugated
anti-CCR7, 0.3 mg/well FITC-conjugated anti-CCR9, 0.2 mg/
well FITC-conjugated anti-CXCR4 or control FITC-conjugated
IgG antibodies at 4uC for 45 min in the dark. These cells were
fixed with 4% paraformaldehyde for 15 min at 4uC and then
washed twice with SAP buffer before staining them with
intracellular markers as such: 0.04 mg/well APC-conjugated
anti-IL-17, 0.1 mg/well PE-conjugated anti-IFNc or isotype
controls antibodies were added in the dark at room temperature
for 45 min. The cells were washed with flow cytometric buffer and
resuspended in the same buffer. FITC-conjugated cells (more than
99% pure) were gated and examined for the production of IL-17
and IFNc.
Treatment with the antibodies
Enriched NK cells were incubated with IL-2 as described
above, in the absence or the presence of these neutralizing
NK17/NK1 Cells Are CCR4
+
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26780antibodies: 1 mg/mL anti-IL-1b, anti-IL-6, anti-IL-21, anti-
TGF-b1 or isotype control antibodies for 6–7 days. The cells
were collected, washed and CD56
+ cells isolated. They were
labeled extracellularly with anti-CCR4 and intracellularly with
anti-IL-17 and anti-IFN-c, and then examined in the flow
cytometry.
Multiple Sclerosis patients
The local ethical committee at Ulleva ˚l Hospital and Oslo
University Hospital approved the study, and patients were
informed and signed consent forms according to the approved
protocol. All patients fulfilled McDonald’s diagnostic criteria. Five
patients with relapsing remitting (RR) MS diagnosis donated blood
samples in a clinical stable phase of the disease and before
receiving any treatment. Three other patients donated CSF
(Table 1). Peripheral blood cells from these patients were
incubated with IL-2 similar to normal blood. Cells from the
CSF were sorted into non-activated CD56
+ and CD56
2, and were
labeled with surface anti-CCR4 and intracellularly with IL-17 and
IFN-c, as described above. Cells isolated from the CSF of a third
MS patient with secondary progressive MS (Table 1) were labeled
with FITC-conjugated anti-CCR4, fixed, permeabilized and
stained with PE-conjugated anti-IFN-c and APC-conjugated
anti-IL-17. They were examined by flow cytometry as described
above.
Detection of IL-17 and IFN-c levels by ELISA assay
Concentrations of IL-17 and IFN-c were determined with the
human Quantikine ELISA kits (R&D Systems Europe Ltd) as
described by the manufacturers’ user manual. Supernatants from
IL-2-activated CD56
+CCR4
+ NK cells (5610
5 or 1610
6 cells/
mL), were collected and the levels of IFNc and IL-17 were
determined at 450 nm with Power wave XS plate reader (Biotec
instruments, VT, USA).
Statistical analysis
Significant values were generated by the Student t-test utilizing
GraphPad Prism 3 software (GraphPad Software, Inc., La Jolla





+ NK cells produce and secrete
IL-17 and IFN-c
To investigate the presence of NK cells secreting IL-17 and
IFN-c in human peripheral blood, we used an approach based on
the finding that chemokine receptor CCR6 is expressed on cells
secreting IL-17 or IL-17 plus IFN-c [13,14]. First, we isolated non-
activated NK cells from normal human blood and sorted them
into CD56
+ and CD56
2 using antibody-coated beads. The surface
of highly purified CD56
+ and CD56
2NK cells were labeled with
FITC-conjugated anti-CCR6. Because NK cells also express
CCR4 [15], and because this molecule is present on Th17 cells in
addition to CCR6 [13,14], we stained non-activated CD56
2 and
CD56
+ NK cells with anti-CCR4. NK cells express most other
chemokine receptors that are involved in their chemotaxis,
migration and cytotoxicity. For example, they express CXCR4
important for their chemotaxis and retention in the bone marrow
[16,17], CCR6 is reported to increase their migration [18,19],
CCR7 is important for their migration and lodging into the lymph
nodes [20,21], and CCR9 involved in migration of cells into the
small intestine is expressed on a subset of NK cells [4].
Consequently, we labeled these cells with antibodies to CCR6,
CCR7, CCR9 and CXCR4 receptors. All these subsets of NK
cells were stained intracellularly with PE-conjugated antibody to
IL-17 and IFN-c. The results demonstrate that less than 2% of
non-activated CD56
+ NK cells, or CD56
2K cells that were
labeled with antibodies toward CCR4, CCR6, CCR7, CCR9 or
CXCR4 produced IL-17 or IFN-c (data not shown).
Since NK cells have been shown to secrete these cytokines upon
IL-2 activation [11,12], we activated purified NK cells in vitro with
IL-2 for 7 days and then sorted them into CD56
+ and CD56
2
subsets. First, we ascertained that the CD56
+ NK cells are pure
since they were stained with anti-CD56 and not with anti-CD3 ‘‘T
cells’’, anti-CD14 ‘‘monocytes’’, or anti-CD19 ‘‘B cells’’ (Figure 1).
Cells of both CD56
+ and CD56
2 subsets were labeled with surface
anti-CCR4, anti-CCR6, anti-CCR7, anti-CCR9, or anti-CXCR4
and intracellularly with antibodies toward IL-17 and IFN-c. There




2 cells (data not shown). Based on these preliminary
findings, we examined IL-2 activated CD56
+ cells labeled with
antibody towards CCR4, as well as with anti-CCR6, anti-CCR7,
anti-CCR9 or anti-CXCR4. As shown in Figure 2, about 25%,
14%, 5%, 4% and 11% of IL-2 activated CD56
+ NK cells were
stained with FITC-conjugated anti-CCR4, anti-CCR6, anti-
CCR7, anti-CCR9 and anti-CXCR4, respectively, whereas
isotype control antibodies did not label these cells. FITC-labeled
cells were gated (more than 99% pure), and stained intracellularly
with PE-conjugated anti-IFN-c and APC-conjugated anti-IL-17 or
with isotype controls PE-conjugated and APC-conjugated anti-
bodies. The results demonstrate that only CCR4





+ NK cells were labeled intracellularly
with antibodies to both cytokines (Figure 2). These results indicate
that cells contained within the CD56
+CCR4
+ NK cell subset are
primary targets for polarization into cells producing IL-17 and
IFN-c, designated here as NK17/NK1 synonymous with T cell
terminology [14]. In addition to flow cytometric analysis, we
measured the levels of these cytokine in the supernatants of
NK17/NK1 cells. Results in Figure 3A show that high levels of






Incubating purified NK cells with IL-2 in the absence or
presence of neutralizing antibodies to IL-1b, IL-6, IL-21, or TGF-
b1 did not affect the percentages of CD56
+CCR4
+ cells secreting
Table 1. MS patients examined in this study.
Year born Sample Sex Disease course
1958 PB Female RRMS
1972 PB Male RRMS
1963 PB Female RRMS
1972 PB Female RRMS
1973 PB Male RRMS (early
secondary
progressive MS)
1964 CSF Female RRMS
1986 CSF Female RRMS
1961 CSF Male Secondary
progressive MS
PB=peripheral blood. CSF=cerebrospinal fluid. RRMS=relapsing-remitting MS.
doi:10.1371/journal.pone.0026780.t001
NK17/NK1 Cells Are CCR4
+
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26780Figure 1. Phenotypes of CD56
+ cells. IL-2-activated CD56
+ cells were isolated by EasySep human CD56 positive selection kit. They were examined
for the expression of CD3, CD14, CD19 and CD56. Background control using isotype antibodies are also shown. Numbers indicate the percentage of
positive cells. One of 5 experiments performed.
doi:10.1371/journal.pone.0026780.g001
Figure 2. Only CD56
+CCR4
+ produce IL-17 and IFN-c. CD56
+ NK cells were labeled with FITC-conjugated isotype control antibodies or FITC-
conjugated anti-CCR4, anti-CCR6, anti-CCR7, anti-CCR9 or anti-CXCR4 antibodies. They were also labeled intracellularly with PE-conjugated and APC-
conjugated isotype control antibodies, or PE-conjugated anti- IFN-c and APC-conjugated anti-IL-17 antibodies. FITC-conjugated cells were gated
(more than 99% pure for the expression of a particular chemokine receptor) and examined for the production of IL-17 and IFN-c. Labeling with
isotype control antibodies is also shown. Numbers show the percentage of positive cells. This is a representative experiment of five different donors.
doi:10.1371/journal.pone.0026780.g002
NK17/NK1 Cells Are CCR4
+
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targeted cytokines only IL-2 has the capacity to polarize these cells.
To demonstrate that NK17/NK1 cells express IL-2R, sorted
CD56
+cells were labeled with FITC-conjugated anti-CCR4 and
PE-conjugated anti-IL-2Rb or intracellularly with PE-conjugated
anti-IL-2Rc (common c chain). Data shown in Figure 3C indicate
that CD56
+CCR4
+ cells expressed both IL-2Rb and IL-2Rc.
Further analysis showed that incubating CD56
+ NK cells with
stimuli other than IL-2 such as PMA plus ionomycin overnight did
not generate cells that produce IL-17 plus IFN-c, albeit the
presence of 18% CCR4
+ cells within the CD56
+ cell population
(Figure 3D).
NK17/NK1 cells do not express IL-23R but express RORct,
T-bet and NK cell maturation markers
To gain insights into the expression of NK cell markers among
different NK cell subsets based on their chemokine receptor
possession, we double sorted IL-2-activated NK cells, first into
CD56
+ and then into CCR4
+ or CCR6
+ cells by antibody-
conjugated beads. These subsets were labeled with antibodies to
various surface receptors. The results show that both NK cell
subsets expressed the mature NK cell molecules NKp30, NKp44,
NKp46, NKG2D, CD158 and CD161, but lacked the expression
of immature cell marker CD127. The most obvious difference
between the two subsets is the expression of IL-23 on the surface of
CCR6
+ NK cells and not on NK17/NK1 (CD56
+CCR4
+) cells
(P,0.03, Figure 4A). Notably, NK17/NK1 cells expressed the
ligand for CCR4, i.e. CCL22/MDC, suggesting that this
chemokine may play a role in the maintenance and/or survival
of these cells.
To gain further insights into the molecular pathways involved in
the production of IL-17 and IFN-c, we examined the expression of
the transcription factors RORct and T-bet important for the
secretion of IFN-c a n dI L - 1 7 ,r e s p e c t i v e l y[ 2 2 , 2 3 ] .H e n c e ,s o r t e d
CD56
+CCR4
+NK cells were labeled withanti-T-bet or anti-RORct.





+ cells, and examined for the levels of IL-17 and IFN-c by ELISA. Mean6SEM of three experiments. B) Enriched CD56
+ NK cells were
incubated with IL-2 only (no treatment), or with IL-2 plus neutralizing antibodies to IL-1b, IL-6, IL-21, TGF-b1, or a combination of isotype control goat
and mouse antibodies for 6 days. The cells were collected, and labeled with FITC-conjugated anti-CCR4 and intracellularly with PE-conjugated
antibodies to IL-17 and IFN-c. Mean6SEM of positive cells collected from the blood of three donors. C) CD56
+ NK cells were labeled with isotype
control (not shown) or FITC-conjugated anti-CCR4 and PE-conjugated anti-IL-2Rb antibodies or intracellularly with PE-conjugated anti-common c
chain (IL-2Rc). Numbers show the percentages of positive cells. D) CD56
+ NK cells were incubated overnight with 100 ng/mL PMA plus ionomycin.
FITC-conjugated CCR4 cells were gated and examined for the production of IL-17 and IFN-c. Labeling with isotype control antibodies is also shown.
Numbers show the percentages of positive cells.
doi:10.1371/journal.pone.0026780.g003
NK17/NK1 Cells Are CCR4
+
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+CCR4
+ NK cells stained with
antibodies to RORct or T-bet (Figure 4B), suggesting that these
transcription factors are important for the production of IL-17 and
IFN-c by these cells. On the other hand, CD56
+CCR4
2 cells did not
express RORct but about 40% of them expressed T-bet (Figure 4B).
NK17/NK1 cells are increased in the cerebrospinal fluid
(CSF) of multiple sclerosis (MS) patients
Both Th1 secreting IFN-c and Th17 secreting IL-17 contribute
to the pathogenesis of MS and EAE. Consequently, we examined
the presence of NK17/NK1 cells in the blood of patients with MS.
The results from five different patients show that NK17/NK1 cells
were not spontaneously found in the blood, but were generated
from the peripheral blood of four patients examined upon
activation with IL-2, although their frequencies were less than in
normal blood (Figure 5A). Of note, blood samples were collected
from MS patients age 25–53 years old, which were not different
from samples collected from healthy donors. We have also
included CSF from MS patients due to the possibility that this
may give us an idea about the role these cells might play in a
diseased organ. After isolation of non-activated CD56
+ cells from
the CSF of two MS patients, CCR4
+ cells secreting both IL-17 and
IFN-c were abundant (Figure 5B). The frequency of
CD56
+CCR4
+ cells (NK17/NK1 cells) was about ten-fold higher
than CD56
2CCR4
+ cells found in the CSF (Figure 5B vs. 5C), and
more than twenty-fold the numbers of non-activated
CD56
+CCR4
+ found in the peripheral blood of MS patients
(Figure 5B vs. 5A). Also, we managed to obtain enough cells from
the CSF of a third MS patient which were labeled with FITC-
conjugated anti-CCR4 and intracellularly with PE-conjugated
anti-IFN-c and APC-conjugated anti-IL-17. The results in
Figure 5D demonstrate that about 25% of CCR4
+ NK cells
produced both IL-17 and IFN-c. It is highly plausible that NK17/
NK1 cells may migrate from the periphery into the CSF aided by
the CCL22/CCR4 axis, and are polarized in the brain due to
inflamed local microenvironment that may contribute to their
generation. CSF of normal individuals was not collected due to
ethical considerations. However, NK cells are either not found or
found in very low numbers in the brain of normal mice [24].
Discussion
We describe here a novel subset of human NK cells






2, expressing mature NK cell markers, the ligand for
CCR4, and producing IL-17 and IFN-c. Earlier findings show
that NK cells can be classified into different subsets based on their
Figure 4. Expression of various markers by NK17/NK1 cells. A) IL-2-activated CD56
+ NK cells were sorted by antibody-coated beads into
CCR4
+ or CCR6
+ and then labeled with antibodies to various cell markers. The numbers are generated from 3 donors and are shown as mean6SEM. P
value compares the frequency of CCR4
+ and CCR6
+ positive cells expressing IL-23R. B) CD56
+ NK cells were sorted into CCR4
+ or CCR4
2and then
labeled intracellularly with antibodies to RORct and T-bet. Background using isotype control antibodies are shown in black. Numbers indicate the
percentage of positive cells.
doi:10.1371/journal.pone.0026780.g004
NK17/NK1 Cells Are CCR4
+
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26780expression of chemokine receptors [4], but the functions of these
subsets are not known. Our results are the first to show that a
subset of human NK cells expressing a specific chemokine receptor
perform distinguished function related to the production of
inflammatory cytokines.
Because NK17/NK1 cells differ from both Th17 and NK22
since they do not express CCR6 or IL-23R, they may represent a
distinct subset of NK cells. NK cells should have multiple
specialized lineages or subsets since they perform multiple tasks
[25]. Further, NK cells have memory similar to adaptive T cells
indicating that various subsets or lineages of these cells may be
recalled in response to various pathogens or cytokines. Under
pathological conditions where IL-2 is released, we anticipate that
NK17/NK1 cells predominate, which may affect the microenvi-
ronment through the release of IL-17 and IFN-c. Intriguingly
however, is the lack of any subset of NK cells examined in this
study that can secrete only IFN-c. This includes CD56
+ or CD56
2





only cells that secrete IFN-c also secrete IL-17 (i.e. NK17/NK1
cells). It is either that cells of this subset are the only producers of
this cytokine, or that IFN-c is released by other NK cell subsets not
examined in this study. The observation that CD56
+ cells devoid
of CCR4 express T-bet transcription factor suggests that cells
lacking CCR4





might also secrete IFN-c.
The finding that NK17/NK1 cells do not express IL-23R,
whereas CCR6
+ cells express it but do not produce IL-17 or IFN-
c, suggests that in the periphery the role of IL-23 may be replaced
with available cytokines such as IL-2. Hence, IL-23 inducing the
release of IL-17 may be a property of NK cells found at mucosal
Figure 5. NK17/NK1 cells are abundant in the CSF of MS patients. A) NK cells were isolated from the blood of MS patients. CD56
+ cells were
isolated and labeled with FITC-conjugated anti-CCR4 and intracellularly with PE-conjugated anti-IL-17 and anti-IFN-c. Each dot represents the
percentage of CD56
+CCR4
+ cells producing IL-17 and IFN-c from an individual patient before and after activation with IL-2. B) CSF from two MS
patients (P1 and P2) were sorted into CD56
+ NK cells and then labeled with FITC-conjugated anti-CCR4, PE-conjugated anti-IL-17, and PE-conjugated
anti-IFN-c. Numbers show percentages of cells producing IL-17 and IFN-c. C) This is similar to panel B, except that CD56
- NK cells isolated from the
same MS patients were examined. D) Cells from the CSF of a third MS patient were labeled with isotype control (not shown) or FITC-conjugated anti-
CCR4 antibody and intracellularly with isotype control (not shown), or PE-conjugated anti-FITC and APC-conjugated anti-IL-17 antibodies. FITC-
conjugated cells were gated (more than 99% positive for CCR4 expression), and examined for the production of intracellular cytokines. Numbers
show the percentage of positive cells.
doi:10.1371/journal.pone.0026780.g005
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of regulation are different in the periphery and at inflamed sites
where more mature NK cells predominate. Plausibly, NK cells
exposed in the periphery to IL-2 generate NK17/NK1 cells that
express CCR4, whereas those that are exposed to IL-23 in the
mucosa generate NK22 cells that express CCR6. Further, NK17/
NK1 cells present in the periphery express RORct
+ and T-bet
+
transcription factors, which facilitate their secretion of IL-17 and
IFN-c.
The role of NK cells in MS/EAE is controversial and it is not
yet clear whether NK cells ameliorate or exacerbate the disease
[10,26]. We recently reported that administration of glatiramer
acetate (GA) a drug used to treat MS patients, reduced EAE
clinical score in SJL mice corroborated with isolating NK cells that
expressed high killing potential against immature or mature
dendritic cells [24]. In addition, administration of anti-Tac
(Daclizumab) antibody to MS patients ameliorated the disease,
associated with induced expansion and activation of CD56
+ NK
cells [27]. These findings demonstrate that NK cells may
contribute to the therapeutic efficacy of these drugs.
In summary, we have identified a new subset of human NK cells
that has not been previously recognized. The cells of this subset are
designated as NK17/NK1 cells because they produce and secrete
IL-17 and IFN-c. They are generated from the peripheral blood of
healthy individuals as well as MS patients upon activation with IL-
2, and are abundant in the CSF of MS patients. The precise role
that NK17/NK1 play in MS and other autoimmune diseases is
currently under investigation.
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